Diversified Healthcare Trust – (NASDAQ:DHCNI) Short Interest Down 61.5% in August

Diversified Healthcare Trust – (NASDAQ:DHCNI) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 5,918 shares, a decline of 61.5% from the August 15th total of 15,391 shares. Based on an average trading volume of 12,605 shares, the short-interest ratio is currently 0.5 days.

Diversified Healthcare Trust Price Performance

NASDAQ:DHCNI traded up $0.19 during mid-day trading on Friday, hitting $17.89. 7,703 shares of the company’s stock traded hands, compared to its average volume of 53,073. Diversified Healthcare Trust has a 12 month low of $15.61 and a 12 month high of $19.09. The firm has a 50 day moving average of $18.15 and a two-hundred day moving average of $17.96.

Diversified Healthcare Trust Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Saturday, August 1st. Shareholders of record on Wednesday, July 15th were given a $0.3516 dividend. This represents a $1.41 annualized dividend and a yield of 7.9%. The ex-dividend date was Wednesday, July 15th.

Diversified Healthcare Trust (NASDAQ: DHCNI) is a publicly traded real estate investment trust (REIT) specializing in healthcare and life science properties. The company’s primary business activities include the acquisition, development, ownership and management of net‐leased medical office buildings, senior housing facilities and life science research and development assets. In addition to property investments, Diversified Healthcare Trust holds mortgage loans and preferred equity interests in the healthcare sector, offering diversified exposure to both real estate and structured financing arrangements.

The company’s portfolio spans a broad range of healthcare asset types, including medical office buildings leased to health systems and physician groups, senior living communities operated by leading care providers, and life science campuses serving biotechnology and pharmaceutical companies.